Drug intelligence / Profile preview

C2101

Development stage: Unknown
Lead developer: JW Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

C2101 is a calcium channel inhibitor being developed by JW Pharmaceutical Corp. It is being studied in combination with JW0101 (an HMG-CoA reductase inhibitor) for the treatment of dyslipidemia and hypertension. The combination product is designed to simultaneously address both conditions, which often co-occur in patients. The drug has completed Phase 3 clinical trials as of 2025.

Brand names: LivaloVA

Targets

CaV (Voltage-gated calcium channel protein complex)

Beyond the preview

Go deeper on C2101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C2101.

Explore the full profile